Qiming Corporate GP VI, Ltd. sold $8.6M of ALMR (indirect holdings)
Qiming Corporate GP VI, Ltd. sold 280,458 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at an average of $30.56 ($29.35–$31.07, $8.57M total) across 20 trades over 2026-10-23 to 2026-10-26. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).
How this was made
The 30-second read
Why it matters
The disclosed sale reduces insider ownership to ~1.74M shares, potentially influencing investor perception.
Market read
Primary insider sale for a micro‑cap biotech; modest trading relevance.
What to watch
The 10b5‑1 plan was not pre‑arranged, indicating the sale was discretionary.
Background
Form 4 filings disclose insider transactions; Qiming entities collectively own ~10% of ALMR.
Ticker impact
Form 4 shows Qiming Corporate GP VI, Ltd. sold ~280k shares of ALMR for $8.57M, reducing its stake.
likely pressure as the market prices in the insider sell
The sale is sizable for a micro‑cap and was executed at market prices, suggesting a neutral to negative sentiment.
Market effects
Minimal impact on the broader biotech sector; only reflects a single insider's position.
No regional effect beyond the company's share price.
Limited to investors tracking micro‑cap biotech stocks.
Counterpoint
The sale could be a routine portfolio rebalancing rather than a negative signal.
Key entities
- CompanyAlamar Biosciences, Inc.
Biotech firm listed on NASDAQ under ticker ALMR.
- InsiderQiming Corporate GP VI, Ltd.
10% owner of ALMR filing the sale.
